How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines
Abstract
The HIV pandemic continues to pose a major global public health challenge.Despite the success of antiretroviral therapy (ART), access to lifelong treatment for all people living with HIV (PLWH) worldwide is not universal or affordable, and is compromised by recent changes in the funding landscape, highlighting the need for preventative vaccines.Two large efficacy trials of a single broadly neutralizing antibody (bNAb), VRC01, provided evidence that bNAbs can block acquisition by antibody-sensitive HIV strains, corroborating previous studies in non-human primates.These trials provided proof-of-principle for antibody-mediated protection, and generated essential biological insights that strengthened HIV vaccine development [ 1 ].
Fields of Study & Subjects
HIV Research and Treatment
Immune responses and vaccinations
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Journal of the International AIDS Society
- Publisher
- Wiley
- Volume
- 29
- Issue
- 5
- Pages
- e70119–e70119
- Publication date
- 1 May 2026
- Language
- EN